Shares of Cellect Biotechnology Ltd. (NASDAQ:APOP) traded today at $7.15, eclipsing its 52-week high. Approximately 13.1 million shares have changed hands today, as compared to an average 30-day volume of 215,000 shares.
Cellect Biotechnology Ltd is a biotechnology company that has developed a novel technology platform known as ApoGraft that functionally selects cells in order to improve the safety and efficacy of regenerative medicine and cell therapies. The company is developing its first product based on its ApoGraft technology platform, the ApoTainer kit that utilizes FasL- apoptotic protein.
Cellect Biotechnology Ltd. share prices have moved between a 52-week high of $7.15 and a 52-week low of $1.35 and are now trading 317% above that low price at $5.63 per share.
Cellect Biotechnology Ltd. (NASDAQ:APOP) is currently priced 22.7% above its average consensus analyst price target of $4.35.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer